Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review.
Level 5 - mechanism / opinion, no new human data
Systematic review of preclinical (in vitro and animal) mechanistic studies
PubMed 39493366 · doi:10.2147/COPD.S474512
What was done
A systematic review was conducted to evaluate the effect of N-acetylcysteine (NAC) on airway mucus hypersecretion, specifically analyzing its impact on MUC5AC and MUC5B mucin gene and protein expression and goblet cell hyperplasia across in vitro and animal models (including COPD models).
What was found
The review reported that NAC exerted inhibitory effects on MUC5AC and MUC5B gene and protein expression and reduced the number of goblet cells. The abstract reported no specific numerical data, effect sizes, or statistical metrics.
Why it matters
These findings suggest that NAC acts not only as a mucolytic but also as a direct mucoregulator that dampens mucin synthesis, pointing to potential therapeutic utility in COPD phenotypes driven by mucus hypersecretion.
Limits
The abstract does not disclose the number of included studies, search strategy, or quantitative effect estimates. The summarized evidence is confined to in vitro and animal models, with an explicit lack of data from human bronchial tissue and clinical validation.
Cited by
- supports N-acetylcysteine (NAC) helps remove mucus from the body.